GT Biopharma, Inc. (GTBP) Stock Forecast
GTBP analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $75.00 average of analyst targets
- Upside to target
- +966.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-2.50
- 52-week range
- $5.24 – $23.02
GTBP analyst ratings
1 analystsNumber of analysts at each rating.
GTBP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GTBP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.50 | −$2.50 | −$2.50 | −$20.75 | +87.9% | 1 |
| Current fiscal year (2026) | −$10.75 | −$10.75 | −$10.75 | −$167.00 | +93.6% | 1 |
| Next fiscal year (2027) | −$8.00 | −$8.00 | −$8.00 | −$10.75 | +25.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GTBP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
GTBP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GTBP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.00 | −$2.00 | −$2.00 | −$2.00 | −$2.50 | +25.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$8.50 | −$8.50 | −$8.50 | −$8.50 | −$10.75 | +26.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$6.75 | −$6.75 | −$6.75 | −$6.75 | −$8.00 | +18.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GTBP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GTBP beat in 6 of 12.
What analysts expect from GTBP
1 analysts cover GT Biopharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $75.00, 966.9% above the latest close of $7.03. Analysts expect earnings of −$10.75 per share for 2026, +93.6% from a year earlier. For 2027 the average estimate is −$8.00 per share. GT Biopharma beat the EPS estimate in 6 of the last 12 quarters.
Related: GTBP income statement, GTBP key metrics, GTBP chart. See the GTBP stock overview for the latest quote and news.
GTBP forecast FAQ
What is GT Biopharma's price target?
The average analyst price target for GT Biopharma is $75.00, 966.9% above the latest close of $7.03.
Is GT Biopharma a buy, hold or sell?
Of 1 analysts covering GT Biopharma, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is GT Biopharma's EPS forecast?
Analysts forecast −$10.75 per share for 2026 (range −$10.75 to −$10.75); for 2027 the estimate is −$8.00.
When does GT Biopharma report earnings?
GT Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-2.50.
Does GT Biopharma usually beat earnings estimates?
GT Biopharma reported EPS at or above the analyst estimate in 6 of the last 12 quarters.